GTHX (G1 Therapeutics) Cash Flow from Others : $0.20 Mil (TTM As of Jun. 2024)

View and export this data going back to 2017. Start your Free Trial

What is G1 Therapeutics Cash Flow from Others?

G1 Therapeutics's cash flow from others for the three months ended in Jun. 2024 was $0.63 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Jun. 2024 was $0.20 Mil.

G1 Therapeutics Cash Flow from Others Historical Data

The historical data trend for G1 Therapeutics's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

G1 Therapeutics Cash Flow from Others Chart

G1 Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Others

Get a 7-Day Free Trial

0.24

2.29

3.13

-0.19

G1 Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Cash Flow from Others	Get a 7-Day Free Trial															-0.54	-0.34	-0.23	0.15	0.63

G1 Therapeutics Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.20 Mil.

G1 Therapeutics Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of G1 Therapeutics's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.

G1 Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » G1 Therapeutics Inc (NAS:GTHX) » Definitions » Cash Flow from Others

Comparable Companies

Traded in Other Exchanges

N/A

Address

700 Park Offices Drive, Suite 200, Research Triangle Park, NC, USA, 27709

Website

https://www.g1therapeutics.com

G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine and enhance the anti-tumor activity of current therapies. Its product COSELA indicates to help protect bone marrow from the damage of chemotherapy.

Executives

John V. Umstead	officer: Chief Financial Officer	C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Bailey John E. (jack) Jr.	director, officer: President and CEO	C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Rajesh Malik	officer: Chief Medical Officer	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Andrew Perry	officer: Chief Commercial Officer	C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Mark Avagliano	officer: Chief Business Officer	79 T.W. ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Terry L Murdock	officer: Chief Operating Officer
Monica R. Thomas	officer: General Counsel	700 PARK OFFICES, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Mark A. Velleca	director, officer: President and CEO	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Jennifer K. Moses	officer: CFO	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
James S. Hanson	officer: General Counsel	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Norman Sharpless	director	700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 22709
Jacks Lee	director	700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Seth Rudnick	director	7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS, MISSISSAUGA A6 L5N 0E4
Alicia Secor	director	33 HAYDEN AVE., LEXINGTON MA 02421
Soma Gupta	officer: Chief Commercial Officer	C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709